Lung cancer study aims to personalize immunotherapy dosing

NCT ID NCT06195527

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 16, 2026 · Updated 23 times

Summary

This study looks at whether regularly measuring the amount of pembrolizumab (an immunotherapy drug) in the blood can help doctors better treat non-small cell lung cancer. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. About 75 adults with this type of lung cancer who are already receiving pembrolizumab will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Angers University Hospital
RECRUITING

Angers, 49000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
CH Le Mans
NOT_YET_RECRUITING

Le Mans, 53000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER